Bioconjugation presents an new frontier for pharmaceutical development, providing an option for improved drug efficacy across ...
ADC Therapeutics could claim its first product approval in the US next May, after the FDA started a priority review of lead drug Lonca for diffuse large B-cell lymphoma (DLBCL), an aggressive form ...
The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) ...
Fresh off a pivot from commercial pharma business to preclinical biotech, Aadi Bioscience has rebranded to better match its ...
Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...
Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 ...
As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...
"Tissue factor (TF) is a validated ADC target with overexpression in many high unmet need solid tumor indications, however, the currently approved TF targeting ADC has severe limitations due to a ...
Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side ...
Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02
ADCE-T02 is a potential first-in-class Topoisomerase I inhibitor-based antibody-drug conjugate (ADC) targeting tissue factor, a validated ADC target overexpressed in multiple solid tumors Phase I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback